<DOC>
	<DOC>NCT01782924</DOC>
	<brief_summary>This study is designed to evaluate safety and efficacy of long-term exposure of KHK4827 in subjects with moderate to severe plaque psoriasis who have completed the preceding Study 4827-002.</brief_summary>
	<brief_title>A Phase 3 Clinical Study of KHK4827</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Subject has voluntarily signed the written informed consent form to participate in this study Subject has completed the week 12 evaluation of Study 4827002 Subject has had a serious infection, defined as requiring systemic treatment with antibiotics or antivirals (excluding oral administration) Subject has been judged to be ineligible for participation in the study by the investigators/subinvestigators</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>